Allogene疗法 ALLO 深 沪
等待开盘 05-14 09:30:00 美东时间
2.33
+0.030
+1.30%
华盛通- 最 高2.35
- 今 开2.31
- 成交量 638.33万股
- 最 低 2.22
- 昨 收 2.30
- 总市值 8.04亿
- 52周最高 4.46
- 市盈率 静 --
- 换手率 1.85%
- 52周最低 0.9842
- 委 比 -80.40%
- 总股本 3.45亿
- 历史最高 55.00
- 量 比 1.00
- 振 幅 5.65%
- 历史最低 0.8621
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Allogene Highlights ALPHA3 Data and Extended Cash Runway
An announcement from Allogene Therapeutics ( ($ALLO) ) is now available. On May...
52分钟前
Allogene Therapeutics Q1 EPS $(0.18) Beats $(0.19) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 35.71 percent increase over losses of $(0.28) per share
今天 04:02
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
Initial clinical data for AlloNK in refractory rheumatoid arthritis (RA) shows 71% ACR50 response at six months, with no relapses or new immunomodulatory agents needed. The treatment demonstrated good tolerability, supporting outpatient administration in community settings without cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Over 70 autoimmune patients have been treated across 40 clinical site...
05-08 10:30
Allogene Therapeutics Receive South Korea, Australia Clearance To Expand Its Pivotal Phase 2 ALPHA3 Trial Of Cemacabtagene Ansegedleucel To Treat Patients With Large B-Cell Lymphoma
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that regulatory
04-21 20:31
Allogene Therapeutics to present allogeneic CAR-T data at AACR annual meeting
Allogene Therapeutics to present allogeneic CAR-T data at AACR annual meeting Allogene Therapeutics will present at AACR Annual Meeting in San Diego, April 17-22, 2026. Preclinical BCMA/CD70 dual CAR T poster session scheduled for April 20, 9:00 a.m.-12:00 p.m. PT. CEO David Chang will speak in majo
04-20 20:36
Allogene presents preclinical BCMA/CD70 dual CAR-T data for multiple myeloma at AACR
Allogene presents preclinical BCMA/CD70 dual CAR-T data for multiple myeloma at AACR Allogene Therapeutics disclosed new preclinical work on an allogeneic dual-target CAR-T program targeting BCMA and CD70 for high-risk multiple myeloma. Data will be presented at AACR 2026 on April 20 in a poster ses
04-20 20:31
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
JP Morgan Upgrades Allogene Therapeutics to Neutral
JP Morgan analyst Brian Cheng upgrades Allogene Therapeutics (NASDAQ:ALLO) from Underweight to Neutral.
04-16 23:05
U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial Services
U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial Services April 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CME Group, M&T Bank and PNC Financial Services on Thursday. HIGHLIGHTS * Allogene Therapeutics In
04-16 15:55
